EFFICACY AND SAFETY OF BEMPEDOIC ACID IN LIPID DISORDER THERAPY: A REVIEW OF CLINICAL TRIALS

被引:0
作者
Dabrowska, Paulina [1 ]
Zuber, Michal [2 ]
Dacka, Michal [3 ]
机构
[1] Stefan Cardinal Wyszynski Prov Specialist Hosp Lub, Al Krasnicka 100, PL-20718 Lublin, Poland
[2] Independent Publ Clin Hosp 4 Lublin, Ul Kazimierza Jaczewskiego 8, PL-20954 Lublin, Poland
[3] 1 Mil Clin Hosp Lublin, Al Raclawickie 23, PL-20049 Lublin, Poland
来源
PROSPECTS IN PHARMACEUTICAL SCIENCES | 2024年 / 22卷 / 03期
关键词
KEYWORDS: bempedoic acid; nonstatin therapy; statin intolerance; atherosclerotic cardiovascular disease; ATHEROSCLEROTIC CARDIOVASCULAR-DISEASE; LOWERING THERAPIES; CHOLESTEROL; STATINS;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
LDL level is a key risk factor for atherosclerotic cardiovascular disease. Bempedoic acid is an innovative hypolipemic drug, particularly useful for patients with statin intolerance. The article focuses on analyzing the results of clinical trials on the mechanisms of action, efficacy and safety of bempedoic acid used both as monotherapy and in combination with other hypolipemic drugs. Scientific evidence based on the CLEAR: Tranquility, Harmony, Serenity, Wisdom, Outcomes study, among others, is presented. Its significant effects on lowering LDL-C, non-HDL-C, and hsCRP levels are highlighted, with important implications for the prevention and treatment of cardiovascular disease. It also outlines how bempedoic acid is included in current Polish guidelines for the treatment of lipid disorders. The paper also points to new areas of research, including potential applications of bempedoic acid in specific patient groups, such as pregnant women. In addition, the article addresses issues related to the longterm use and safety of bempedoic acid, particularly in the context of reducing cardiovascular risk and lowering blood lipid levels, which is crucial for patients with statin intolerance.
引用
收藏
页码:120 / 126
页数:7
相关论文
共 46 条
  • [11] Clinical Trials.gov, Effect of Bempedoic Acid on Liver Fat in Individuals With Nonalcoholic Fatty Liver Disease and Type 2 Diabetes (B-LIFT)
  • [12] Clinical Trials.gov, Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women
  • [13] Clinical Trials.gov, Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP) (ARTCAP)
  • [14] Clinical Trials.gov, Bempedoic Acid Pregnancy Surveillance Program
  • [15] Clinical Trials.gov, Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)
  • [16] Lipoproteins, Cholesterol, and Atherosclerotic Cardiovascular Disease in East Asians and Europeans
    Doi, Takahito
    Langsted, Anne
    Nordestgaard, Borge G.
    [J]. JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2023, 30 (11) : 1525 - 1546
  • [17] Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition A Narrative Review
    Duarte Lau, Freddy
    Giugliano, Robert P.
    [J]. JAMA CARDIOLOGY, 2023, 8 (09) : 879 - 887
  • [18] European Medicines Agency, Nustendi
  • [19] European Medicines Agency, Nilemdo
  • [20] ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK
    Filippov, Sergey
    Pinkosky, Stephen L.
    Lister, Richard J.
    Pawloski, Catherine
    Hanselman, Jeffrey C.
    Cramer, Clay T.
    Srivastava, Rai Ajit K.
    Hurley, Timothy R.
    Bradshaw, Cheryl D.
    Spahr, Mark A.
    Newton, Roger S.
    [J]. JOURNAL OF LIPID RESEARCH, 2013, 54 (08) : 2095 - 2108